Neuphoria Therapeutics (NEUP) Net Income towards Common Stockholders (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted Net Income towards Common Stockholders of -$4.95 million for fiscal Q4 2026 (quarter ended Jun 30, 2026), compared with -$8.91 million a year earlier.
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), Neuphoria Therapeutics' Net Income towards Common Stockholders came in at -$13.5 million.
- In prior fiscal years, Neuphoria Therapeutics' Net Income towards Common Stockholders was -$400,000 in FY2025, -$15.5 million in FY2024, -$21.29 million in FY2023 and $654,220 in FY2022 (-4.8%).
- Quarterly Net Income towards Common Stockholders has run from a low of -$9.91 million in fiscal Q1 2026 to a high of $11.3 million in fiscal Q3 2025 over five years.
- According to Business Quant data, Net Income towards Common Stockholders for the three prior fiscal quarters was -$505,063 (Q3 2026), $1.86 million (Q2 2026) and -$9.91 million (Q1 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Neuphoria Therapeutics | 431.33 Mn | 356.14 Mn | - | -4.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.95 Mn |
| Mar 31, 2026 | -505,063.00 |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | -804,787.00 |
| Jun 30, 2024 | -2.69 Mn |
| Mar 31, 2024 | -2.78 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |
API Access
Neuphoria Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();